Browsing by title
Now showing items 2575-2594 of 4628
-
MAP4K4 Inhibitors
(2019-04-18)This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these ... -
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.
(BMJ PUBLISHING GROUP, 2018-10-01)OBJECTIVE: Oesophageal cancer is the seventh most common cause of cancer-related death worldwide. Disease relapse is frequent and treatment options are limited. DESIGN: To identify new biomarker-defined therapeutic approaches ... -
Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology.
(RADIOLOGICAL SOC NORTH AMERICA, 2018-09-01)Purpose To cross-validate T1-weighted oxygen-enhanced (OE) MRI measurements of tumor hypoxia with intrinsic susceptibility MRI measurements and to demonstrate the feasibility of translation of the technique for patients. ... -
Mapping Local Failure Following Bladder Radiotherapy According to Dose.
(ELSEVIER SCIENCE LONDON, 2022-06-09)AIMS: To determine the relationship between local relapse following radical radiotherapy for muscle-invasive bladder cancer (MIBC) and radiation dose. MATERIALS AND METHODS: Patients with T2-4N0-3M0 MIBC were recruited to ... -
Mapping the 3D structures of small molecule binding sites
(BMC, 2016-12-06) -
Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking.
(NATURE PORTFOLIO, 2020-03-27)Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to determine how a patient's cancer is evolving ... -
Mapping the dynamic immune landscape associated with therapeutic response in soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2023-10-24)Soft tissue sarcomas (STS) are a group of rare and heterogenous cancers of unmet need. In the advanced setting, and following failure of first-line anthracycline therapy, further line therapeutic options offer limited ... -
Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium.
(SPRINGER, 2021-07-18)While being in a committed relationship is associated with a better prostate cancer prognosis, little is known about how marital status relates to its incidence. Social support provided by marriage/relationship could promote ... -
Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac - Feasibility, workflow data and patient acceptance.
Introduction Stereotactic body radiotherapy (SBRT) is an established ablative treatment for liver tumors with excellent local control rates. Magnetic resonance imaging guided radiotherapy (MRgRT) provides superior soft ... -
Markers predictive of response, resistance and relapse in colorectal cancer
(Institute of Cancer Research (University Of London), 2021-05-31)Response to neo-adjuvant chemo-radiotherapy (CRT) in locally advanced rectal cancer varies. Circulating tumour DNA (ctDNA) has emerged as a surrogate marker of the tumour genome. I hypothesised that ctDNA could be an early ... -
Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma.
(AMER ASSOC CANCER RESEARCH, 2020-07-01)PURPOSE: Immune dysregulation is described in multiple myeloma. While preclinical models suggest a role for altered T-cell immunity in disease progression, the contribution of immune dysfunction to clinical outcomes remains ... -
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆.
(ELSEVIER, 2021-02-06)BACKGROUND: Approved first-line treatments for patients with BRAF V600-mutant advanced melanoma include nivolumab (a programmed cell death protein 1 inhibitor) plus ipilimumab (a cytotoxic T lymphocyte antigen-4 inhibitor; ... -
Maternal and fetal cardiometabolic recovery following ultrasound-guided high-intensity focused ultrasound placental vascular occlusion.
(ROYAL SOC, 2019-05-31)High-intensity focused ultrasound (HIFU) is a non-invasive method of selective placental vascular occlusion, providing a potential therapy for conditions such as twin-twin transfusion syndrome. In order to translate this ... -
Maternal breast cancer risk in relation to birthweight and gestation of her offspring.
(BMC, 2018-10-05)BACKGROUND: Parity and age at first pregnancy are well-established risk factors for breast cancer, but the effects of other characteristics of pregnancies are uncertain and the literature is inconsistent. METHODS: In a ... -
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
(PUBLIC LIBRARY SCIENCE, 2018-01-01)Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively ... -
Mathematical modelling of subclonal interactions in paediatric high-grade gliomas
(Institute of Cancer Research (University Of London), 2022-05-31)Despite a low overall mutational burden, paediatric high-grade gliomas (pHGG) display high intra-tumour heterogeneity. Accumulating evidence suggest the presence of cellular mechanisms that maintain such high heterogeneity, ... -
Maximising the potential of AKT inhibitors as anti-cancer treatments.
(PERGAMON-ELSEVIER SCIENCE LTD, 2017-04-01)PI3K/AKT signalling is commonly disrupted in human cancers, with AKT being a central component of the pathway, influencing multiple processes that are directly involved in tumourigenesis. Targeting AKT is therefore a highly ... -
MCPH1 inhibits Condensin II during interphase by regulating its SMC2-Kleisin interface.
(eLife Sciences Publications, Ltd, 2021-12-01)Dramatic change in chromosomal DNA morphology between interphase and mitosis is a defining features of the eukaryotic cell cycle. Two types of enzymes, namely cohesin and condensin confer the topology of chromosomal DNA ... -
MDC1 Interacts with TOPBP1 to Maintain Chromosomal Stability during Mitosis.
(CELL PRESS, 2019-05-02)In mitosis, cells inactivate DNA double-strand break (DSB) repair pathways to preserve genome stability. However, some early signaling events still occur, such as recruitment of the scaffold protein MDC1 to phosphorylated ...